$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold

$fold Overview Financials Valuation SEC Filings Company Website

2019 Q2 Form 10-Q Financial Statement

#000117887919000039 Filed on May 09, 2019

Income Statement

Concept	2019 Q2	2019 Q1	2018 Q1
Revenue	$44.13M	$34.05M	$16.70M
YoY Change	107.1%	103.92%	300.38%
Cost Of Revenue	$5.367M	$4.055M	$2.615M
YoY Change	71.2%	55.07%	235.26%
Gross Profit	$38.76M	$29.99M	$14.08M
YoY Change	113.29%	112.99%	315.37%
Gross Profit Margin	87.84%	88.09%	84.34%
Selling, General & Admin	$42.58M	$44.30M	$27.40M
YoY Change	45.96%	61.71%	43.21%
% of Gross Profit	109.84%	147.72%	194.56%
Research & Development	$70.98M	$64.59M	$40.80M
YoY Change	104.79%	58.32%	32.12%
% of Gross Profit	183.12%	215.37%	289.74%
Depreciation & Amortization	$1.154M	$991.0K	$969.0K
YoY Change	18.6%	2.27%	18.17%
% of Gross Profit	2.98%	3.3%	6.88%
Operating Expenses	$115.2M	$111.3M	$70.26M
YoY Change	76.93%	58.36%	26.83%
Operating Profit	-$76.43M	-$81.28M	-$56.18M
YoY Change	62.86%	44.67%	8.02%
Interest Expense	$4.625M	$6.454M	$4.488M
YoY Change	1.43%	43.81%	-227.14%
% of Operating Profit
Other Income/Expense, Net	-$877.0K	$1.086M	$2.764M
YoY Change	-83.5%	-60.71%	353.11%
Pretax Income	-$83.83M	-$120.1M	-$51.31M
YoY Change	36.33%	134.14%	-6.61%
Income Tax	$717.0K	$168.0K	-$1.392M
% Of Pretax Income
Net Earnings	-$84.55M	-$120.3M	-$49.92M
YoY Change	36.74%	141.0%	-9.23%
Net Earnings / Revenue	-191.6%	-353.34%	-298.97%
Basic Earnings Per Share
Diluted Earnings Per Share	-$355.1K	-$563.4K	-$283.7K
COMMON SHARES
Basic Shares Outstanding	230.5M shares	223.7M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q2	2019 Q1	2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$575.7M	$438.3M	$562.5M
YoY Change	6.81%	-22.08%	101.04%
Cash & Equivalents	$220.6M	$96.35M	$114.3M
Short-Term Investments	$355.1M	$342.0M	$448.2M
Other Short-Term Assets	$20.10M	$13.60M	$10.60M
YoY Change	737.5%	28.3%	-1.85%
Inventory	$10.40M	$8.167M	$8.100M
Prepaid Expenses
Receivables	$28.71M	$22.96M	$10.80M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$634.9M	$483.0M	$592.0M
YoY Change	10.18%	-18.4%	99.86%
LONG-TERM ASSETS
Property, Plant & Equipment	$15.27M	$13.29M	$8.900M
YoY Change	67.63%	49.28%	-8.25%
Goodwill	$197.8M	$197.8M
YoY Change	0.0%
Intangibles	$23.00M	$23.00M
YoY Change	0.0%
Long-Term Investments			$42.70M
YoY Change
Other Assets	$12.04M	$11.27M	$5.600M
YoY Change	103.47%	101.16%	93.1%
Total Long-Term Assets	$283.2M	$281.7M	$278.0M
YoY Change	13.42%	1.32%	-60.13%
TOTAL ASSETS
Total Short-Term Assets	$634.9M	$483.0M	$592.0M
Total Long-Term Assets	$283.2M	$281.7M	$278.0M
Total Assets	$918.0M	$764.7M	$870.0M
YoY Change	11.16%	-12.1%	-12.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$84.10M	$60.60M	$43.70M
YoY Change	102.16%	38.67%	10.35%
Accrued Expenses	$2.700M	$2.500M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$89.55M	$65.87M	$140.7M
YoY Change	69.07%	-53.18%	28.38%
LONG-TERM LIABILITIES
Long-Term Debt	$149.1M	$168.8M	$166.8M
YoY Change	-11.98%	1.2%	6.31%
Other Long-Term Liabilities	$3.987M	$3.609M	$34.50M
YoY Change	43.94%	-89.54%	-85.76%
Total Long-Term Liabilities	$3.987M	$3.609M	$201.3M
YoY Change	43.94%	-98.21%	-49.57%
TOTAL LIABILITIES
Total Short-Term Liabilities	$89.55M	$65.87M	$140.7M
Total Long-Term Liabilities	$3.987M	$3.609M	$201.3M
Total Liabilities	$318.0M	$313.0M	$348.4M
YoY Change	20.45%	-10.15%	-48.96%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.600B	-$1.533B	$383.0K
YoY Change	36.17%	-400236.03%
Common Stock	$2.204B	$1.973B
YoY Change	27.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$600.1M	$451.7M	$521.6M
YoY Change
Total Liabilities & Shareholders Equity	$918.0M	$764.7M	$870.0M
YoY Change	11.16%	-12.1%	-12.42%

Cashflow Statement

Concept	2019 Q2	2019 Q1	2018 Q1
OPERATING ACTIVITIES
Net Income	-$84.55M	-$120.3M	-$49.92M
YoY Change	36.74%	141.0%	-9.23%
Depreciation, Depletion And Amortization	$1.154M	$991.0K	$969.0K
YoY Change	18.6%	2.27%	18.17%
Cash From Operating Activities	-$58.48M	-$78.55M	-$49.52M
YoY Change	2.6%	58.61%	-0.64%
INVESTING ACTIVITIES
Capital Expenditures	-$2.170M	$2.944M	$819.0K
YoY Change	104.72%	259.46%	-212.19%
Acquisitions
YoY Change
Other Investing Activities	-$12.90M	$83.01M	-$181.8M
YoY Change	-209.51%	-145.67%	98.28%
Cash From Investing Activities	-$15.07M	$80.07M	-$182.6M
YoY Change	-240.58%	-143.85%	97.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$189.0M	$0.00	$294.6M
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	196.4M	$17.38M	$296.6M
YoY Change	2693.88%	-94.14%	-296679.0%
NET CHANGE
Cash From Operating Activities	-58.48M	-$78.55M	-$49.52M
Cash From Investing Activities	-15.07M	$80.07M	-$182.6M
Cash From Financing Activities	196.4M	$17.38M	$296.6M
Net Change In Cash	122.9M	$16.55M	$65.32M
YoY Change	-413.02%	-74.66%	-145.88%
FREE CASH FLOW
Cash From Operating Activities	-$58.48M	-$78.55M	-$49.52M
Capital Expenditures	-$2.170M	$2.944M	$819.0K
Free Cash Flow	-$56.31M	-$81.49M	-$50.34M
YoY Change	0.66%	61.88%	2.5%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019Q1	dei	Amendment Flag AmendmentFlag	false
CY2019Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2019Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019Q1	dei	Document Period End Date DocumentPeriodEndDate	2019-03-31
CY2019Q1	dei	Document Type DocumentType	10-Q
CY2019Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001178879
CY2019Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	230450221	shares
CY2019Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2019Q1	dei	Entity Registrant Name EntityRegistrantName	AMICUS THERAPEUTICS, INC.
CY2019Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2019Q1	fold	Accumulated Depreciation And Amortization Finance And Operating Right Of Use Leases AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases	2111000	USD
CY2019Q1	fold	Adjustments To Additional Paid In Capital Premiums Paid From Termination Of Capped Call Confirmations AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations	14632000	USD
CY2019Q1	fold	Capped Call Confirmation Current CappedCallConfirmationCurrent	2200000	USD
CY2018Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities CashCashEquivalentsAndAvailableforsaleDebtSecurities	504579000	USD
CY2019Q1	fold	Cash Cash Equivalents And Availableforsale Debt Securities CashCashEquivalentsAndAvailableforsaleDebtSecurities	438170000	USD
CY2018Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	11000	USD
CY2019Q1	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	178000	USD
CY2018Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Loss Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	438000	USD
CY2019Q1	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Loss Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	21000	USD
CY2018Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure	504152000	USD
CY2019Q1	fold	Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure	438327000	USD
CY2019Q1	fold	Contingent Consideration Milestone Payment ContingentConsiderationMilestonePayment	9000000	USD
CY2019Q1	fold	Debt Instrument Convertible Debt Exchange Agreement Accrued And Unpaid Interest DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest	1000000	USD
CY2019Q1	fold	Debt Instrument Convertible Debt Exchange Agreement Aggregate Principal Amount DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount	219300000	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-10875000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3059000	USD
CY2019Q1	fold	Finance And Operating Lease Liabilities Noncurrent FinanceAndOperatingLeaseLiabilitiesNoncurrent	36100000	USD
CY2018Q1	fold	Foreign Currency Remeasurement Gain Loss Before Tax ForeignCurrencyRemeasurementGainLossBeforeTax	2957000	USD
CY2019Q1	fold	Foreign Currency Remeasurement Gain Loss Before Tax ForeignCurrencyRemeasurementGainLossBeforeTax	-325000	USD
CY2019Q1	fold	Lessee Operating Lease Liability Tenant Incentives LesseeOperatingLeaseLiabilityTenantIncentives	152689000	USD
CY2019Q1	fold	Milestone Payment Stock Issued As Consideration MilestonePaymentStockIssuedAsConsideration	9000000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-427000	USD
CY2019Q1	fold	Gain Loss On Extinguishment Of Debt Additional Paid In Capital GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital	190400000	USD
CY2019Q1	fold	Gain Loss On Extinguishment Of Debt Fair Value Of Common Shares Issued GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued	400000	USD
CY2019Q1	fold	Debt Instrument Convertible Debt Exchange Agreement Shares Authorized For Issuance DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance	39000000	shares
CY2019Q1	fold	Finance And Operating Lease Liabilities Current FinanceAndOperatingLeaseLiabilitiesCurrent	2523000	USD
CY2019Q1	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	157000	USD
CY2018Q1	fold	Increase Decrease In Deferred Reimbursements IncreaseDecreaseInDeferredReimbursements	0	USD
CY2019Q1	fold	Increase Decrease In Deferred Reimbursements IncreaseDecreaseInDeferredReimbursements	-1500000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	21962000	USD
CY2018Q1	fold	Increase Decrease In Noncurrent Operating Liabilities IncreaseDecreaseInNoncurrentOperatingLiabilities	-163000	USD
CY2019Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	22960000	USD
CY2019Q1	fold	Increase Decrease In Noncurrent Operating Liabilities IncreaseDecreaseInNoncurrentOperatingLiabilities	-3507000	USD
CY2019Q1	fold	Lessee Operating And Financing Lease Renewal Term LesseeOperatingAndFinancingLeaseRenewalTerm	P25Y
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15671000	USD
CY2019Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15794000	USD
CY2019Q1	fold	Number Of Gene Therapy Programs NumberOfGeneTherapyPrograms	14	program
CY2019Q1	fold	Operating And Finance Lease Right Of Use Assets OperatingAndFinanceLeaseRightOfUseAssets	36308000	USD
CY2018Q1	fold	Payment Of Contingent Consideration PaymentOfContingentConsideration	0	USD
CY2019Q1	fold	Payment Of Contingent Consideration PaymentOfContingentConsideration	9316000	USD
CY2018Q1	fold	Payments For Repurchase Of Restricted Stock Units PaymentsForRepurchaseOfRestrictedStockUnits	1912000	USD
CY2019Q1	fold	Payments For Repurchase Of Restricted Stock Units PaymentsForRepurchaseOfRestrictedStockUnits	1938000	USD
CY2018Q1	fold	Proceeds From Capped Call Confirmations Exchange Of Convertible Debt ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt	0	USD
CY2019Q1	fold	Proceeds From Capped Call Confirmations Exchange Of Convertible Debt ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt	-14600000	USD
CY2019Q1	fold	Proceeds From Capped Call Confirmations Exchange Of Convertible Debt ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt	-14632000	USD
CY2019Q1	fold	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	812000	USD
CY2018Q1	fold	Stock Issued From Equity Financing Value StockIssuedFromEquityFinancingValue	294584000	USD
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	80625000	USD
CY2019Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	60596000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	495000	USD
CY2019Q1	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-1309000	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1740061000	USD
CY2019Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1970607000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	190758000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	0	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	9316000	USD
CY2018Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7478000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12744000	USD
CY2019Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	300000	USD
CY2018Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2601000	USD
CY2019Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1649000	USD
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	63767000	shares
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	32101000	shares
CY2018Q4	us-gaap	Assets Assets	789951000	USD
CY2019Q1	us-gaap	Assets Assets	764702000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	551096000	USD
CY2019Q1	us-gaap	Assets Current AssetsCurrent	483046000	USD
CY2018Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	427084000	USD
CY2019Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	345540000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	11000	USD
CY2019Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	178000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	438000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	424403000	USD
CY2019Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	341978000	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	96349000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51237000	USD
CY2019Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	21000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	424830000	USD
CY2019Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	341821000	USD
CY2019Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	342000000	USD
CY2018Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1100000	USD
CY2019Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1383000	USD
CY2018Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	19700000	USD
CY2019Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	20767000	USD
CY2018Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	19700000	USD
CY2019Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	20767000	USD
CY2018Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	142000	USD
CY2019Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	49060000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	114322000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	79749000	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	96349000	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	96300000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	79749000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	116552000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82375000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	98928000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	65315000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	16553000	USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2019Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	189383924	shares
CY2019Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	230180714	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	189383924	shares
CY2019Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	230180714	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	1942000	USD
CY2019Q1	us-gaap	Common Stock Value CommonStockValue	2347000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-52162000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-121519000	USD
CY2018Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	175006000	USD
CY2019Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	22052000	USD
CY2018Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2615000	USD
CY2019Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4055000	USD
CY2018Q1	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	0	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	403100000	USD
CY2019Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	100400000	USD
CY2018	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0	USD
CY2019Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-1383000	USD
CY2017Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	25400000	USD
CY2019Q1	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0	USD
CY2018Q4	us-gaap	Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent	2732000	USD
CY2019Q1	us-gaap	Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent	3613000	USD
CY2018Q4	us-gaap	Deferred Credits And Other Liabilities Current DeferredCreditsAndOtherLiabilitiesCurrent	5500000	USD
CY2019Q1	us-gaap	Deferred Credits And Other Liabilities Current DeferredCreditsAndOtherLiabilitiesCurrent	2750000	USD
CY2018Q4	us-gaap	Deferred Credits And Other Liabilities Noncurrent DeferredCreditsAndOtherLiabilitiesNoncurrent	10156000	USD
CY2019Q1	us-gaap	Deferred Credits And Other Liabilities Noncurrent DeferredCreditsAndOtherLiabilitiesNoncurrent	11406000	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	6465000	USD
CY2019Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	6465000	USD
CY2018Q1	us-gaap	Depreciation Depreciation	969000	USD
CY2019Q1	us-gaap	Depreciation Depreciation	991000	USD
CY2019Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	80600000	USD
CY2018Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	507400000	USD
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.28
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.56
CY2018Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	860000	USD
CY2019Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-2350000	USD
CY2018Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-1100000	USD
CY2018Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	26500000	USD
CY2018Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	28700000	USD
CY2019Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	20767000	USD
CY2018Q1	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	4861000	USD
CY2019Q1	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	0	USD
CY2019Q1	us-gaap	Finance Lease Impairment Loss FinanceLeaseImpairmentLoss	100000	USD
CY2019Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	75000	USD
CY2018Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	4861000	USD
CY2018Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	4900000	USD
CY2019Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	USD
CY2018Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2019Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-36123000	USD
CY2019Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-36100000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	197797000	USD
CY2019Q1	us-gaap	Goodwill Goodwill	197797000	USD
CY2018Q1	us-gaap	Gross Profit GrossProfit	14081000	USD
CY2019Q1	us-gaap	Gross Profit GrossProfit	29991000	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-51308000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-120131000	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1392000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	168000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-10347000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-8858000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1047000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23000000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1001000	USD
CY2018Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3253000	USD
CY2019Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-345000	USD
CY2019Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23000000	USD
CY2018Q1	us-gaap	Interest Expense InterestExpense	4488000	USD
CY2019Q1	us-gaap	Interest Expense InterestExpense	6454000	USD
CY2018Q1	us-gaap	Interest Paid Net InterestPaidNet	12000	USD
CY2019Q1	us-gaap	Interest Paid Net InterestPaidNet	4846000	USD
CY2018Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3614000	USD
CY2019Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3805000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	8390000	USD
CY2019Q1	us-gaap	Inventory Net InventoryNet	8167000	USD
CY2018Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1291000	USD
CY2019Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1321000	USD
CY2018Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	200000	USD
CY2018Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	3485000	USD
CY2019Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	3041000	USD
CY2018Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	1737000	USD
CY2019Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	2639000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	220040000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	174006000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	10830000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	10418000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	10516000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	9776000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	4494000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	28939000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	447039000	USD
CY2019Q1	us-gaap	Liabilities Liabilities	313034000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	789951000	USD
CY2019Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	764702000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	86125000	USD
CY2019Q1	us-gaap	Liabilities Current LiabilitiesCurrent	65869000	USD
CY2018Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	22432000	USD
CY2019Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	24380000	USD
CY2018Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	424403000	USD
CY2019Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	341978000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	296579000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	17384000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-182603000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	80065000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-49521000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-78546000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-49916000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-120299000	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	70263000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	111270000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-56182000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-81279000	USD
CY2019Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1400000	USD
CY2019Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	2100000	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	38412000	USD
CY2019Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2421000	USD
CY2019Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	35991000	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	36208000	USD
CY2019Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.128
CY2019Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P14Y219D
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	30887000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	3611000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	3371000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	3560000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	4063000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	10038000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	6244000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6683000	USD
CY2019Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11265000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-441000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	584000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1805000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1804000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	0	USD
CY2019Q1	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	0	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-83199000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2246000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1220000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2853000	USD
CY2019Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3609000	USD
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2764000	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1086000	USD
CY2018Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	303010000	USD
CY2019Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	52178000	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	819000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2944000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	16592000	USD
CY2019Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13592000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	294584000	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2018Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	121226000	USD
CY2019Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	135187000	USD
CY2018Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3978000	USD
CY2019Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3953000	USD
CY2018Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2019Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	812000	USD
CY2018Q1	us-gaap	Profit Loss ProfitLoss	-49916000	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	-120299000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2177000	USD
CY2018Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2230000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1412222000	USD
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2626000	USD
CY2019Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2579000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11375000	USD
CY2019Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13286000	USD
CY2018Q1	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	71000	USD
CY2018Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	40798000	USD
CY2019Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	64593000	USD
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1532521000	USD
CY2018Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	16696000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	34046000	USD
CY2019Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	19500000	USD
CY2018Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	146734000	USD
CY2019Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	146766000	USD
CY2018Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	27396000	USD
CY2019Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	44303000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7478000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	12744000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-1912000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-1940000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	7478000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	12744000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3978000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3953000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	352850000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	521617000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	342912000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	451668000	USD
CY2018Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	13063000	USD
CY2019Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	12387000	USD
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	175977700	shares
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	213519287	shares
CY2019Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on cash and cash equivalents or its marketable securities.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;">. The Company's accounts receivable at </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> have arisen from product sales primarily in the EU and U.S. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined and the Company evaluates the creditworthiness of each customer on a regular basis.</font></div></div>
CY2019Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassification</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain prior year amounts have been reclassified for comparative purposes. The reclassifications did not affect results of operations, net assets or cash flows.</font></div></div>
CY2019Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001178879-19-000039-index-headers.html	Edgar Link	pending
0001178879-19-000039-index.html	Edgar Link	pending
0001178879-19-000039.txt	Edgar Link	pending
0001178879-19-000039-xbrl.zip	Edgar Link	pending
amicus-03312019x10q.htm	Edgar Link	pending
exhibit101toform10-q2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
fold-03312019xex311.htm	Edgar Link	pending
fold-03312019xex312.htm	Edgar Link	pending
fold-03312019xex321.htm	Edgar Link	pending
fold-20190331.xml	Edgar Link	completed
fold-20190331.xsd	Edgar Link	pending
fold-20190331_cal.xml	Edgar Link	unprocessable
fold-20190331_def.xml	Edgar Link	unprocessable
fold-20190331_lab.xml	Edgar Link	unprocessable
fold-20190331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold

2019 Q2 Form 10-Q Financial Statement

#000117887919000039 Filed on May 09, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FOLD AMICUS THERAPEUTICS, INC. Stock $fold

2019 Q2 Form 10-Q Financial Statement

#000117887919000039 Filed on May 09, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold